| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print April 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Physiological Nursing, University of California, San Francisco, San Francisco, CA 94143-0160
Corresponding Author: bradley.aouizerat{at}nursing.ucsf.edu
Recent discovery and characterization of apolipoprotein A-V (APOAV) suggests a role in metabolism of triglyceride-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma triglycerides (TG) in normolipidemic samples. The aims of this study were to assess: the effects of a polymorphism in APOAV (T-1131C) in terms of its frequency among three dyslipidemic and a control population; differences of allele frequency across available ethnic groups; and associations with specific lipoprotein TG and cholesterol (C) compartments. We found a striking elevation in the frequency of the rare allele in a Chinese population (p=0.0002) compared to Hispanic and European populations. The rare allele of the polymorphism was associated with elevated plasma TG (p=0.012), VLDL-C (p=0.0007) and VLDL–TG (p=0.012), LDL-TG (p=0.003) and HDL-TG (p=0.016). Linear regression models predict that possession of the rare allele elevates plasma TG by 21 mg/dL (p=0.009), VLDL-C by 8 mg/dL (p=0.0001) and reduces HDL-C by 2 mg/dL (p=0.017). The association of the polymorphism with altered lipoprotein profiles was observed in combined hyperlipidemia, hypoalphalipoproteinemia, hyperalphalipoproteinemia and in controls. These findings indicate that APOAV is an important determinant of plasma triglyceride, lipoprotein cholesterol and is potentially a risk factor for cardiovascular disease.
Revised on March 4, 2003
Accepted on March 18, 2003
Genetic analysis of a polymorphism in the human apolipoprotein A-V gene: effect on plasma lipids
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. R. Pullinger, B. E. Aouizerat, I. Movsesyan, V. Durlach, E. J. Sijbrands, K. Nakajima, A. Poon, G. M. Dallinga-Thie, H. Hattori, L. L. Green, et al. An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients J. Lipid Res., August 1, 2008; 49(8): 1846 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Yamada, S Ichihara, K Kato, T Yoshida, K Yokoi, H Matsuo, S Watanabe, N Metoki, H Yoshida, K Satoh, et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people J. Med. Genet., January 1, 2008; 45(1): 22 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Grallert, E.-M. Sedlmeier, C. Huth, M. Kolz, I. M. Heid, C. Meisinger, C. Herder, K. Strassburger, A. Gehringer, M. Haak, et al. APOA5 variants and metabolic syndrome in Caucasians J. Lipid Res., December 1, 2007; 48(12): 2614 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sundl, M. Guardiola, G. Khoschsorur, R. Sola, J. C. Vallve, G. Godas, L. Masana, M. Maritschnegg, A. Meinitzer, N. Cardinault, et al. Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene 1131T>C variant and associations with plasma lipids and lipid peroxidation J. Lipid Res., November 1, 2007; 48(11): 2506 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice J. Lipid Res., July 1, 2007; 48(7): 1476 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Elosua, J. M. Ordovas, L. A. Cupples, C.-Q. Lai, S. Demissie, C. S. Fox, J. F. Polak, P. A. Wolf, R. B. D'Agostino Sr., and C. J. O'Donnell Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study J. Lipid Res., May 1, 2006; 47(5): 990 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Hodoglugil, S. Tanyolac, D. W. Williamson, Y. Huang, and R. W. Mahley Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks J. Lipid Res., January 1, 2006; 47(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Schultze, W. E. Alborn, R. K. Newton, and R. J. Konrad Administration of a PPAR{alpha} agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio J. Lipid Res., August 1, 2005; 46(8): 1591 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-O. Olofsson ApoA-V: The Regulation of a Regulator of Plasma Triglycerides Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1097 - 1099. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nowak, A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M.-R. Taskinen, J. Fruchart-Najib, et al. Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor Mol. Cell. Biol., February 15, 2005; 25(4): 1537 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. O'Brien, W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins Clin. Chem., February 1, 2005; 51(2): 351 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Q. Lai, S. Demissie, L. A. Cupples, Y. Zhu, X. Adiconis, L. D. Parnell, D. Corella, and J. M. Ordovas Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study J. Lipid Res., November 1, 2004; 45(11): 2096 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Schaap, P. C. N. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. F. M. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis J. Biol. Chem., July 2, 2004; 279(27): 27941 - 27947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-f. Wang, X. Liu, J. O'Connell, Z. Peng, R. M. Krauss, D. L. Rainwater, J. L. VandeBerg, Edward. M. Rubin, J.-F. Cheng, and L. A. Pennacchio Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons Hum. Mol. Genet., May 15, 2004; 13(10): 1049 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mar, P. Pajukanta, H. Allayee, M. Groenendijk, G. Dallinga-Thie, R. M. Krauss, J. S. Sinsheimer, R. M. Cantor, T. W.A. de Bruin, and A. J. Lusis Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia Circ. Res., April 16, 2004; 94(7): 993 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study J. Lipid Res., April 1, 2004; 45(4): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-Q. Lai, E-S. Tai, C. E. Tan, J. Cutter, S. K. Chew, Y.-P. Zhu, X. Adiconis, and J. M. Ordovas The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore J. Lipid Res., December 1, 2003; 44(12): 2365 - 2373. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
